The clinical-stage biotech featured in today’s article, focused on developing treatments for fibrosis, cancer and other related diseases, has gained 18.7% over the past month. In order to determine whether it can continue its ascension and become a winner in the biotech industry, the author takes a look at the factors that could influence its performance in the coming months.…
Companies involved in stem cell therapies, cannabis overdose treatments, COVID-19 vaccinations and the treatment of lupus make up the four new biotech stocks to watch highlighted in today’s article, which also highlights a number of new stocks to watch in the mining sector (including those involved in “battery metals” such as graphite and lithium). For all of these new stocks…
Strong and sustained share price appreciation, solid upside potential, an outlook toward further growth, and approval from Wall Street analysts characterize the three “monster growth stocks” highlighted in today’s article – all of which are hovering at or near one-year highs and have the potential to reach new highs. For these three stocks – including a developmental-stage biopharmaceutical company focused…
Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up ……
“There are massive opportunities in the gene-editing space, but there are also a number of risks investors should know before jumping in,” advise the authors of today’s article. For a discussion of the risks associated with this exciting space that investors should keep in mind, CLICK HERE.
A push to ramp up production of successful COVID-19 vaccines, continued demand for effective COVID-19 treatments, and an increased focus on other critical, non-COVID diseases are driving growth in the biotech industry – and against this backdrop, the author of today’s article highlights four particular biotech stocks that should see significant growth in the coming months. For these four stocks,…
While the author of today’s article acknowledges that, “Of course, it can be challenging for investors to navigate around the complexities that come with the biotech industry,” he advises that, “with proper research and due diligence, investors could make educated guesses on which biotech stocks to bet on.” So which biotech stocks are worth watching heading into June? For the…
“These are five stocks for aggressive investors looking to get share count leverage on biotech companies that have sizable upside potential,” says the author of today’s article of the five biotech stocks he highlights – all of which are trading under the $10 level and are rated “Overweight” at Oppenheimer. For these five biotech stocks, CLICK HERE.
“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
“I think this is the ground floor of a market that could be worth more than $29 billion by the end of the decade,” declares the author of today’s article of the “New Biotech” sector he discusses: psychedelics. For more on the potential profit opportunities associated with the “Shroom Boom” – especially in light of recent news regarding an important, successful FDA…